SYNGR2 plays a tumor-promoting role in lung adenocarcinoma through PI3K-AKT signaling pathway

Abstract

Abstract Objectives To analyze the expression level of SYNGR2 in lung adenocarcinoma, explored its prognostic and diagnostic value, and preliminarily discussed its mechanism of action. Methods The diagnostic value was assessed by generating the ROC curve using SYNGR2 expression data. COX regression and correlation analysis were conducted to establish its association with clinical features. Additionally, immunohistochemical staining was performed on samples from 20 patients with lung adenocarcinoma (LUAD) to validate the observed differences in expression levels. Furthermore, silencing of SYNGR2 in LUAD cells demonstrated inhibition of proliferation, invasion, migration, and colony formation abilities. Moreover, GO and KEGG analyses along with PPI analysis were employed to preliminarily investigate the underlying mechanism of SYNGR2 in lung adenocarcinoma. Results The results demonstrated an upregulation of SYNGR2 which was associated with shorter overall survival (OS) and progression-free survival (PFS). Furthermore, the receiver operating characteristic (ROC) curve analysis revealed a robust diagnostic value for SYNGR2. Additionally, the SYNGR2 gene exhibited a strong association with the PI3K-AKT signaling pathway. Conclusions SYNGR2 plays a tumor-promoting role in lung adenocarcinoma and may act through PI3K-AKT signaling pathway.